Highbridge Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Highbridge Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-50,400	Closed	-$321K	–	93
2020 Q1	$321K	Sell	50,400 -1,277,800	-96%	-$10.3M	0.03%	77
2019 Q4	$13.8M	Buy	+1,328,200	New	+$9.66M	1.53%	28
2017 Q4	–	Sell	-6,000	Closed	-$493K	–	2062
2017 Q3	$493K	Buy	+6,000	New	+$476K	0.01%	929
2015 Q3	–	Sell	-2,800	Closed	-$246K	–	1891
2015 Q2	$246K	Buy	+2,800	New	+$240K	﹤0.01%	1213
2014 Q4	–	Sell	-17,300	Closed	-$785K	–	1507
2014 Q3	$785K	Buy	17,300 +500	+3%	+$20.9K	0.01%	738
2014 Q2	$696K	Buy	+16,800	New	+$865K	0.01%	659

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Highbridge Capital Management's CLVS Position: Q1 2018 in Review

Highbridge Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 50,266 shares — an estimated $3.42M sold.

Highbridge Capital Management first reported a position in CLVS in Q1 2016 and held it in 7 quarters. The position peaked at $4.12M in Q3 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

Highbridge Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 50,266 Clovis Oncology, Inc. shares in Q1 2018, an estimated $3.42M.
Highbridge Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 7 quarters.
Highbridge Capital Management's Clovis Oncology, Inc. position peaked at $4.12M in Q3 2017.
229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.